Nurix Therapeutics (NRIX) Stock Price, News & Analysis

Company Overview

Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development. Among these are targeted protein degraders designed to eliminate key signaling proteins implicated in B-cell malignancies and inflammatory disorders. Nurix advances both proprietary and partnered assets, leveraging its Maestro™ platform to generate novel therapeutic candidates that reflect its expertise in medicinal chemistry, structural biology and protein degradation technologies.

Founded in 2015 and headquartered in San Francisco, California, Nurix collaborates with leading pharmaceutical companies to accelerate discovery and development. These strategic alliances complement the company’s in-house capabilities, enabling the translation of early research into clinical candidates and enhancing its capacity to address diseases that have proved difficult to treat with conventional approaches.

Under the leadership of Chief Executive Officer Christalynn Sayers and an experienced management team, Nurix Therapeutics continues to advance its proprietary pipeline through clinical trials and regulatory engagements. The company remains committed to pioneering new modalities that selectively dismantle disease drivers, with the goal of delivering transformative medicines to patients worldwide.

Key Stats

• Today's Range: $22.91 to $23.90
• 50-Day Range: $14.64 to $24.69
• 52-Week Range: $8.19 to $25.08
• Volume: 1.25 million shs
• Average Volume: 1.12 million shs
• Market Capitalization: $2.45 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $34.00
• Consensus Rating: Moderate Buy

Nurix Therapeutics Stock Analysis - MarketRank™

Nurix Therapeutics scored higher than 53% of companies evaluated by MarketBeat, and ranked 446th out of 833 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Nurix Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on no strong buy ratings, 13 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Nurix Therapeutics has a consensus price target of $34.00, representing about 44.2% upside from its current price of $23.58.

Amount of Analyst Coverage

Nurix Therapeutics has been the subject of 14 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Nurix Therapeutics are expected to grow in the coming year, from ($2.84) to ($2.10) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Nurix Therapeutics is -6.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Nurix Therapeutics is -6.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Nurix Therapeutics has a P/B Ratio of 6.08. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

18.57% of the float of Nurix Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Nurix Therapeutics has a short interest ratio ("days to cover") of 13.87, which indicates bearish sentiment.

Change versus previous month

Short interest in Nurix Therapeutics has recently increased by 1.02%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Nurix Therapeutics does not currently pay a dividend.

Dividend Growth

Nurix Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.62

News Sentiment

Nurix Therapeutics has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.86 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Nurix Therapeutics this week, compared to 5 articles on an average week.

Search Interest

Only 3 people have searched for NRIX on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.

MarketBeat Follows

4 people have added Nurix Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

Company Ownership

• Score: 1.0 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Nurix Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $590,925.00 in company stock.

Percentage Held by Insiders

6.70% of the stock of Nurix Therapeutics is held by insiders.

Percentage Held by Institutions

Nurix Therapeutics has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 7/09/2026
• Today: 7/31/2026
• Next Earnings (Estimated): 10/08/2026
• Fiscal Year End: 11/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:NRIX
• CIK: 1549595
• Web: www.nurixtx.com
• Phone: 415-660-5320
• Fax: N/A
• Employees: 300
• Year Founded: 2012

Price Target and Rating

• Average Price Target for Nurix Therapeutics: $34.00
• High Price Target: $45.00
• Low Price Target: $25.00
• Potential Upside/Downside: +44.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 15 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.45)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$264.46 million
• Net Margins: -928.44%
• Pretax Margin: -929.18%
• Return on Equity: -76.09%
• Return on Assets: -57.31%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.34
• Quick Ratio: 6.34

Sales & Book Value

• Annual Sales: $36.77 million
• Price / Sales: 66.56
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.88 per share
• Price / Book: 6.08

Miscellaneous

• Outstanding Shares: 103,782,000
• Free Float: 96,829,000
• Market Cap: $2.45 billion
• Optionable: Optionable
• Beta: 1.80